Trial Profile

A Phase 1b Study of Neoadjuvant ASP2138 Monotherapy and Investigator's Choice of Adjuvant Chemotherapy in Participants With Resectable Pancreatic Ductal Adenocarcinoma Whose Tumors Have Claudin (CLDN) 18.2 Expression

Status: Not yet recruiting

Phase of Trial: Phase I

Latest Information Update: 11 Jul 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs ASP 2138 (Primary) ; Capecitabine; Fluorouracil; Folinic acid; Gemcitabine; Irinotecan; Oxaliplatin; Paclitaxel
Indications Adenocarcinoma; Pancreatic ductal carcinoma
Focus Adverse reactions
Sponsors Astellas Pharma Global Development

03 Jul 2025 Planned End Date changed from 31 Oct 2027 to 30 Nov 2027.
03 Jul 2025 Planned primary completion date changed from 31 Oct 2027 to 30 Nov 2027.
03 Jul 2025 Planned initiation date changed from 30 Jun 2025 to 31 Jul 2025.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com